New data strengthens teva's schizophrenia portfolio, including phase 3 solaris trial survey results demonstrating patient and healthcare professional satisfaction with tev-'749 (olanzapine) as a once-monthly subcutaneous long-acting injectable

Parsippany, n.j. and tel aviv, israel, march 31, 2025 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced the presentation of a patient and healthcare professional (hcp) attitudes and experiences survey study, complementing the successful phase 3 subcutaneous olanzapine extended-release injection study (solaris) evaluating tev-'749. more than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about tev-'749, overall, including initiation regimen, monthly dosing schedule and dosing options.1 the data were presented at the 2025 congress of the schizophrenia international research society (sirs) taking place from march 29 to april 2, 2025, in chicago, il.
TEVA Ratings Summary
TEVA Quant Ranking